Neuronoff Secures Major Funding for Neuromodulation Innovations
Neuronoff, Inc., a trailblazer in minimally invasive neuromodulation solutions, has unveiled significant funding milestones totaling $5 million to bolster its pioneering Injectrode technology. The funding will play a pivotal role in advancing research aimed at addressing chronic conditions like neurogenic bladder and overactive bladder.
Funding Breakdown and Collaborative Efforts
The funding includes an impressive $1.73 million from the Department of Defense (DOD), earmarked for a clinical randomized controlled trial on the treatment of neurogenic bladder following spinal cord injury. Meanwhile, the National Institutes of Health (NIH) has granted $3.2 million to facilitate preclinical research aimed at refining overactive bladder treatment methodologies.
In concert with the University of Texas Health Science Center in Houston, the DOD funding will enhance the clinical evaluation over three years. This comprehensive study, titled "Home Neuromodulation for Neurogenic Bladder Management in Spinal Cord Injury: A Hybrid Implementation-Effectiveness Trial," will rigorously assess the safety and efficacy of the Injectrode when implanted along the tibial nerve in spinal cord injury patients.
Innovative Clinical Trial Aspects
One of the innovative features of the study is the Injectrode Tibial Nerve Stimulation (iTNS) protocol. Researchers will evaluate the procedure’s effectiveness through an 8-week self-administered treatment period versus a sham treatment, with a keen focus on its mechanisms of action. The study aims to assess the complete elimination of overactive bladder (OAB) medications, as well as the percentage reduction in OAB medications from the beginning of the study to its conclusion. This important phase 1/2 trial is set to yield invaluable data that will guide FDA presubmission engagements and the framework for future pivotal trials.
Addressing the Challenge of Neurogenic Bladder
Dr. Argyrios Stampas, the principal investigator for the clinical trial, expressed the need for innovative solutions: "Neurogenic bladder is a significant complication associated with spinal cord injury. Current treatments lack long-term reliability and often come with adverse drug-related effects. The Injectrode’s needle-based delivery is anticipated to minimize patient risk while facilitating broader therapy access."
In tandem, an NIH preclinical research project titled "An Injectable Electrode to Better Isolate the Posterior Tibial Nerve to Treat OAB" has secured a five-year grant worth $3.2 million. This venture is a collaborative effort among the University of Wisconsin, Case Western Reserve University, and Massachusetts General Hospital, aimed at enhancing treatment efficacy for patients with Overactive Bladder (OAB). This innovative research will leverage the Injectrode's unique two-component, passive injectable electrode system to improve nerve interfacing.
Innovative Approaches to OAB Treatment
Dr. Kip Ludwig, who leads the preclinical OAB research, expressed enthusiasm about the potential impacts of their work: "This innovative injection tool, featuring embedded fiber optics for visualization, enables optimal minimally invasive electrode placement for stimulating the posterior tibial nerve to alleviate overactive bladder symptoms."
Neuronoff's Total Funding and Future Prospects
This recent funding surge elevates Neuronoff's total secured financing to $9.1 million, underscoring robust support from federal and state entities for the company’s advanced micro-invasive neuromodulation therapies. Previous backing included grants from NIH HEAL, DARPA, Ohio Third Frontier Research, and programs aimed at commercializing emerging technologies.
Dr. Manfred Franke, Neuronoff's CEO, emphasized the potential for these funding opportunities to reshape neuromodulation therapy views: "The continued investment underscores the promise of micro-invasive solutions for managing chronic conditions. We aim to transform neurostimulation from a 'last resort' therapy into a viable treatment option. Our needle-based approach allows for easier patient access, aiming to significantly reduce healthcare costs while advancing treatment options for conditions ranging from pain to bladder management."
About Neuronoff
Neuronoff, rooted in innovation, focuses on minimally invasive neuromodulation solutions. Its flagship product, the Injectrode, represents a revolutionary direction in treating chronic conditions by providing drug-free and non-opioid alternatives for a range of ailments, including chronic pain and bladder disorders.
Frequently Asked Questions
What is the Injectrode technology?
The Injectrode technology is a minimally invasive solution designed for neuromodulation therapies, targeting chronic conditions without the need for invasive surgeries.
How much funding did Neuronoff receive?
Neuronoff secured a total of $5 million in funding from various sources, including the DOD and NIH, to further its research and clinical trials.
What conditions is Neuronoff targeting?
Neuronoff's technology primarily focuses on treating conditions such as neurogenic bladder and overactive bladder, in addition to other chronic health issues.
Who are the collaborators involved in the research?
Collaborators include the University of Texas Health Science Center, University of Wisconsin, Case Western Reserve University, and Massachusetts General Hospital.
What impact do the new funding initiatives aim to achieve?
The funding initiatives aim to optimize the Injectrode technology to enhance treatment accessibility, reduce healthcare costs, and improve outcomes for patients with chronic conditions.
